Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.48 |
| ▸ | ITGAL | P20701 | 2/20 | 0.48 |
| ▸ | ECE1 | P42892 | 8/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963481 | 0.91 | MAPT (0.45) | ECE1ACEKMT2A | |
| SCHEMBL5964512 | 0.88 | ACE (0.52) | ITGB2ICAM1ITGALECE1ACE | |
| SCHEMBL5964517 | 0.88 | ACE (0.52) | ITGB2ICAM1ITGALECE1ACE | |
| SCHEMBL5963197 | 0.80 | MAPT (0.47) | ECE1ACEKMT2A | |
| SCHEMBL1853071 | 0.79 | ECE1 (0.49) | ITGB2ICAM1ITGALECE1ALOX15 | |
| SCHEMBL7230352 | 0.78 | ACE (0.61) | ITGB2ICAM1ITGALECE1ALOX15 | |
| SCHEMBL7222010 | 0.78 | ACE (0.63) | ECE1ACE | |
| SCHEMBL8360275 | 0.77 | ALOX15 (0.61) | ITGB2ICAM1ITGALECE1ALOX15 | |
| SCHEMBL7223833 | 0.77 | ECE1 (0.73) | ECE1ALOX15ACE | |
| SCHEMBL489801 | 0.77 | ECE1 (0.73) | ECE1ALOX15ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430045-B1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | NOVARTIS AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | FINK CYNTHIA A | 2006-08-31 | — | — | US | disclosed |
| US-7071169-B2 | Pyrane derivatives as both ACE-and NEP-inhibitors | NOVARTIS AG (CH) | 2006-07-04 | — | — | US | disclosed |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | FINK CYNTHIA ANNE (US) | 2004-12-30 | — | — | US | disclosed |
| EP-1430045-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | Novartis AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027091-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS | NOVARTIS AG (CH) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | ECE1, ECE2, AGTR1 | ITGB2 4808/4885ICAM1 1670/4885ITGAL 4827/4885 |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | ECE1, AGTR1, ACE | ITGB2 4736/4885ICAM1 710/4885ITGAL 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.